LBPH: חוב לטווח קצר של החברה Longboard Pharmaceuticals, Inc.

The price trend for Longboard Pharmaceuticals (LBPH) on GURU.Markets currently stands at 0.00. Longboard Pharmaceuticals develops epilepsy treatments, though its stability depends on the success of Bexicaserin trials and regulatory approval amid a shortage of funds. The business model relies on external contractors for manufacturing and research. The firm is currently scaling operations, preparing for final drug trials following a successful second phase.

This metric measures the aggregate of liabilities with a maturity of up to one year, allowing for a comparison of the company's liquidity against its current debt burdens to assess default risk. For Longboard Pharmaceuticals (LBPH), whose revenues depend on clinical trial results within the stable neurology sector, the volume of short-term borrowings serves as an indicator of financial stability while awaiting the market launch of its drugs.